Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Paz-Ares

P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-Line (1L) Treatment of Advanced NSCLC

Journal of Thoracic Oncology

English

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology

English

P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study

Journal of Thoracic Oncology

English

140PD: LUX-Lung 7: A Phase IIb, Global, Randomised, Open-Label Trial of Afatinib vs Gefitinib as First-Line Treatment for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring Activating EGFR Mutations

Journal of Thoracic Oncology

English

P2.12-04 Liposomal Irinotecan vs Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on/After Platinum-Based Therapy

Journal of Thoracic Oncology

English

P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status With Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients

Journal of Thoracic Oncology

English

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology

English

MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

Journal of Thoracic Oncology

English

PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC

Journal of Thoracic Oncology

English

P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) With Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Paz-Ares

P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-Line (1L) Treatment of Advanced NSCLC

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study

140PD: LUX-Lung 7: A Phase IIb, Global, Randomised, Open-Label Trial of Afatinib vs Gefitinib as First-Line Treatment for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring Activating EGFR Mutations

P2.12-04 Liposomal Irinotecan vs Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on/After Platinum-Based Therapy

P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status With Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC

P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) With Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients